[Minutes, Advisory Committee to the Director GP-160 Meeting (1992: Bethesda, Maryland)]

1 be very well controlled for.
2 The last point that actually came up at,
3 I think, the Office of Technology Transfer seminar
4 which was held the other day, Dr. Redfield mentioned
5 -- and I throw this open to the audience because I
6 don't know the answer -- that his finding was that
7 when the regimen was changed apparently to q monthly
8 times six, his endpoints markedly went up.
9 The concern I'm throwing out is that one
10 should have large clinical trials going on, but I
11 think one should also have innovative trials looking
12 at either a variation of peptide, variation of regimen
13 because we may be missing the boat otherwise in terms
14 of looking at one particular type of regimen.
15 CO-CHAIRMAN CARPENTER: Thank you very
16 much.
17 Tony, would you like to respond?
18 CO-CHAIRMAN FAUCI: The points you make
19 are all well-taken. There certainly are a number of
20 Phase I trials that are ongoing and/or planned to
21 answer many of the questions that you asked about
22 different peptides and different variations.
NEAL R. GROSS
COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVENUE, N.W.
[phone] WASHINGTON, D.C. 20005 [phone]